© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 16, 1230-1237,
August 16, 1995
© 1995 Oxford University Press
Drug Resistance-Associated Marker Lrp for Prediction of Response to Chemotherapy and Prognoses in Advanced Ovarian Carcinoma
Department of Pathology, Free University Hospital Amsterdam, The Netherlands
Department of Oncology, Free University Hospital Amsterdam, The Netherlands
Department of Gynecology, Free University Hospital Amsterdam, The Netherlands
Department of Gynecology, University Hospital Groningen, The Netherlands
Department of Medical Oncology, University Hospital Groningen, The Netherlands
Correspondence to: Prof. Rik J. Scheper, Ph.D., Department of Pathology, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Background: Drug resistance is a major impediment to the successful treatment of ovarian carcinoma. None of the earlier-identified resistance mechanisms, such as overexpression of the MDR1 gene product, P-glycoprotein (Pgp), has been shown to be a major determinant of clinical response to chemotherapy and survival for ovarian cancer patients. The multidrug resistance-associated protein (Mrp) and the lung resistance protein (Lrp, also called the pi 10 major vault protein), are newly described proteins associated with multidrug resistance in vitro. Purpose: The aim of this retrospective study was to investigate the expression of Mrp and Lrp, in addition to Pgp, in advanced ovarian carcinoma and to determine whether such expression was predictive of response to chemotherapy and survival. Methods: Fifty-seven banked frozen specimens, previously collected and frozen at the time of diagnosis from an equal number of patients with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian carcinoma, were immunostained for Pgp (with monoclonal antibodies [MAbs] MRK-16 and JSB-1), Mrp (with MAb MRPrl), and Lrp (with MAb LRP-56). All patients had received platinum- or alkylating-based chemotherapy after debulking surgery. Clinicopathologic parameters determined at diagnosis were retrospectively assessed for their relationship with Pgp, Mrp, and Lrp expression. Response to treatment and survival were compared between Pgp, Mrp, and Lrp expression groups. Qualitative variables were analyzed using Fisher's exact test or the chi-squared test. All reported P values are two-tailed. Results: Nine (16%), 39 (68%), and 44 (77%) of the 57 tumor specimens examined showed positive immuno-staining for Pgp, Mrp, and Lrp, respectively. Positive im-munostaining for these proteins was not associated with any other prognostic factor examined. No association was found between Pgp and Mrp expression and response to chemotherapy and survival. In contrast, patients with Lrp-positive tumors had poorer response to chemotherapy (P =.004) and shorter progression-free (P =.003) and overall (P =.007) survival than Lrp-negative patients. Multivariate analysis of Lrp expression, FIGO stage, residual tumor after initial surgery, tumor grade, and presence or absence of as-cites showed that only Lrp status was independently related to both progression-free survival and overall survival. Conclusions: Positive Lrp immunostaining in advanced ovarian carcinoma appears to be an indicator of poor response to standard chemotherapy (platinum or alkylating agents) and of adverse prognoses. Implications: The functional characterization of Lrp and related proteins may reveal new approaches to modulate Lrp-associated drug resistance. A large prospective study is warranted to confirm the prognostic value of Lrp. [J Natl Cancer Inst 87: 1230–1237, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Bouhamyia, S. Chantot-Bastaraud, S. Zaidi, P. Roynard, C. Prengel, J.-F. Bernaudin, and J. Fleury-Feith Immunolocalization and Cell Expression of Lung Resistance-related Protein (LRP) in Normal and Tumoral Human Respiratory Cells J. Histochem. Cytochem., August 1, 2007; 55(8): 773 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Peters, J. Freund, and R. L. Ochs Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells Mol. Cancer Ther., October 1, 2005; 4(10): 1605 - 1616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsuda, Y. M. Ito, Y. Ohashi, K.-K. Wong, Y. Hashiguchi, W. R. Welch, R. S. Berkowitz, M. J. Birrer, and S. C. Mok Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses Clin. Cancer Res., October 1, 2005; 11(19): 6880 - 6888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, K. Goto, Y. Nishiwaki, T. Kodama, M. Suga, and A. Ochiai Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1691 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. El-Osta, M. Lubbert, P. W. Wijermans, T. Licht, and P. A. Jones On the use of DNA methylation inhibitors and the reversal of transcriptional silencing Blood, February 15, 2003; 101(4): 1656 - 1657. [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohishi, Y. Oda, T. Uchiumi, H. Kobayashi, T. Hirakawa, S. Miyamoto, N. Kinukawa, H. Nakano, M. Kuwano, and M. Tsuneyoshi ATP-binding Cassette Superfamily Transporter Gene Expression in Human Primary Ovarian Carcinoma Clin. Cancer Res., December 1, 2002; 8(12): 3767 - 3775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Duesberg, R. Stindl, and R. Hehlmann Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy PNAS, September 5, 2001; (2001) 201398998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Fracasso, M. F. Brady, D. H. Moore, J. L. Walker, P. G. Rose, L. Letvak, T. M. Grogan, and W. P. McGuire Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., June 15, 2001; 19(12): 2975 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. C. Plaat, H. Hollema, W. M. Molenaar, G. H. T. Broers, J. Pijpe, M. F. Mastik, H. J. Hoekstra, E. van den Berg, R. J. Scheper, and W. T. A. van der Graaf Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins J. Clin. Oncol., September 18, 2000; 18(18): 3211 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filipits, U. Jaeger, I. Simonitsch, C. Chizzali-Bonfadin, H. Heinzl, and R. Pirker Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas Clin. Cancer Res., September 1, 2000; 6(9): 3417 - 3423. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. H. Shoemaker Genetic and Epigenetic Factors in Anticancer Drug Resistance J Natl Cancer Inst, January 5, 2000; 92(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
W. S. Dalton and R. J. Scheper Lung Resistance-Related Protein: Determining Its Role in Multidrug Resistance J Natl Cancer Inst, October 6, 1999; 91(19): 1604 - 1605. [Full Text] [PDF]
|
|
|
|
|
|
M. Kitazono, T. Sumizawa, Y. Takebayashi, Z.-S. Chen, T. Furukawa, S. Nagayama, A. Tani, S. Takao, T. Aikou, and S.-i. Akiyama Multidrug Resistance and the Lung Resistance-Related Protein in Human Colon Carcinoma SW-620 Cells J Natl Cancer Inst, October 6, 1999; 91(19): 1647 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. G. Arts, D. Katsaros, E. G. E. de Vries, M. Massobrio, F. Genta, S. Danese, R. Arisio, R. J. Scheper, M. Kool, G. L. Scheffer, et al. Drug Resistance-associated Markers P-Glycoprotein, Multidrug Resistance-associated Protein 1, Multidrug Resistance-associated Protein 2, and Lung Resistance Protein as Prognostic Factors in Ovarian Carcinoma Clin. Cancer Res., October 1, 1999; 5(10): 2798 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filipits, J. Drach, G. Pohl, J. Schuster, T. Stranzl, J. Ackermann, R. Konigsberg, H. Kaufmann, H. Gisslinger, H. Huber, et al. Expression of the Lung Resistance Protein Predicts Poor Outcome in Patients with Multiple Myeloma Clin. Cancer Res., September 1, 1999; 5(9): 2426 - 2430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. C. Dingemans, M. A. Witlox, R. A. L. M. Stallaert, P. van der Valk, P. E. Postmus, and G. Giaccone Expression of DNA Topoisomerase II{{alpha}} and Topoisomerase II{beta} Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer Clin. Cancer Res., August 1, 1999; 5(8): 2048 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Abbondanza, V. Rossi, A. Roscigno, L. Gallo, A. Belsito, G. Piluso, N. Medici, V. Nigro, A. M. Molinari, B. Moncharmont, et al. Interaction of Vault Particles with Estrogen Receptor in the MCF-7 Breast Cancer Cell J. Cell Biol., June 15, 1998; 141(6): 1301 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Kickhoefer, K. S. Rajavel, G. L. Scheffer, W. S. Dalton, R. J. Scheper, and L. H. Rome Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines J. Biol. Chem., April 10, 1998; 273(15): 8971 - 8974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.L. den Boer, R. Pieters, K.M. Kazemier, M.M.A. Rottier, C.M. Zwaan, G.J.L. Kaspers, G. Janka-Schaub, G. Henze, U. Creutzig, R.J. Scheper, et al. Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia Blood, March 15, 1998; 91(6): 2092 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filipits, G. Pohl, T. Stranzl, R. W. Suchomel, R. J. Scheper, U. Jager, K. Geissler, K. Lechner, and R. Pirker Expression of the Lung Resistance Protein Predicts Poor Outcome in De Novo Acute Myeloid Leukemia Blood, March 1, 1998; 91(5): 1508 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.G.P. Raaijmakers, M.A.I. Izquierdo, H.M. Lokhorst, C. de Leeuw, J.A.M. Belien, A.C. Bloem, A.W. Dekker, R.J. Scheper, and P. Sonneveld Lung-Resistance-Related Protein Expression Is a Negative Predictive Factor for Response to Conventional Low but not to Intensified Dose Alkylating Chemotherapy in Multiple Myeloma Blood, February 1, 1998; 91(3): 1029 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Duhem, F. Ries, and M. Dicato What does Multidrug Resistance (MDR) Expression Mean in the Clinic? Oncologist, June 1, 1996; 1(3): 151 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Giaccone and H. M. Pinedo Drug Resistance Oncologist, February 1, 1996; 1(1): 82 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Pinedo and G. Giaccone P-Glycoprotein -- A Marker of Cancer-Cell Behavior N. Engl. J. Med., November 23, 1995; 333(21): 1417 - 1419. [Full Text]
|
|
|
|
|
|
P. Duesberg, R. Stindl, and R. Hehlmann Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy PNAS, September 25, 2001; 98(20): 11283 - 11288. [Abstract] [Full Text] [PDF]
|
|